Skip to main content
. 2022 Jul 14;181(9):3501–3509. doi: 10.1007/s00431-022-04561-1

Fig. 2.

Fig. 2

Odds ratios and associated 95% confidence intervals for the impact of allergic diseases on the development of long-COVID symptoms in the immunocompetent cohort, both up to 12 weeks and beyond 12-week post-infection